193 related articles for article (PubMed ID: 25449872)
1. Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats.
Suzuki S; Kawamata J; Iwahara N; Matsumura A; Hisahara S; Matsushita T; Sasaki M; Honmou O; Shimohama S
Neurosci Lett; 2015 Jan; 584():276-81. PubMed ID: 25449872
[TBL] [Abstract][Full Text] [Related]
2. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.
Glavaski-Joksimovic A; Virag T; Chang QA; West NC; Mangatu TA; McGrogan MP; Dugich-Djordjevic M; Bohn MC
Cell Transplant; 2009; 18(7):801-14. PubMed ID: 19796495
[TBL] [Abstract][Full Text] [Related]
3. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha.
Wang F; Yasuhara T; Shingo T; Kameda M; Tajiri N; Yuan WJ; Kondo A; Kadota T; Baba T; Tayra JT; Kikuchi Y; Miyoshi Y; Date I
BMC Neurosci; 2010 Apr; 11():52. PubMed ID: 20420688
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
5. Neural metabolite changes in corpus striatum after rat multipotent mesenchymal stem cells transplanted in hemiparkinsonian rats by magnetic resonance spectroscopy.
Fu W; Zheng Z; Zhuang W; Chen D; Wang X; Sun X; Wang X
Int J Neurosci; 2013 Dec; 123(12):883-91. PubMed ID: 23768098
[TBL] [Abstract][Full Text] [Related]
6. Long-term protective effects of AAV9-mesencephalic astrocyte-derived neurotrophic factor gene transfer in parkinsonian rats.
Hao F; Yang C; Chen SS; Wang YY; Zhou W; Hao Q; Lu T; Hoffer B; Zhao LR; Duan WM; Xu QY
Exp Neurol; 2017 May; 291():120-133. PubMed ID: 28131727
[TBL] [Abstract][Full Text] [Related]
7. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 60 affects behavioral improvement in a rat model of Parkinson's disease grafted with human umbilical cord mesenchymal stem cell-derived dopaminergic-like neurons.
Zhao C; Li H; Zhao XJ; Liu ZX; Zhou P; Liu Y; Feng MJ
Neurochem Res; 2016 Jun; 41(6):1238-49. PubMed ID: 26758268
[TBL] [Abstract][Full Text] [Related]
9. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease.
Somoza R; Juri C; Baes M; Wyneken U; Rubio FJ
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1530-40. PubMed ID: 20542127
[TBL] [Abstract][Full Text] [Related]
10. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats.
Suzuki S; Kawamata J; Matsushita T; Matsumura A; Hisahara S; Takata K; Kitamura Y; Kem W; Shimohama S
J Neurosci Res; 2013 Mar; 91(3):462-71. PubMed ID: 23239187
[TBL] [Abstract][Full Text] [Related]
11. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
Chang YL; Chen SJ; Kao CL; Hung SC; Ding DC; Yu CC; Chen YJ; Ku HH; Lin CP; Lee KH; Chen YC; Wang JJ; Hsu CC; Chen LK; Li HY; Chiou SH
Cell Transplant; 2012; 21(1):313-32. PubMed ID: 21669041
[TBL] [Abstract][Full Text] [Related]
12. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
Kikuchi Y; Yasuhara T; Agari T; Kondo A; Kuramoto S; Kameda M; Kadota T; Baba T; Tajiri N; Wang F; Tayra JT; Liang H; Miyoshi Y; Borlongan CV; Date I
J Cell Physiol; 2011 May; 226(5):1390-8. PubMed ID: 20945350
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease.
Chen D; Fu W; Zhuang W; Lv C; Li F; Wang X
J Neurosci Res; 2017 Mar; 95(3):907-917. PubMed ID: 27617772
[TBL] [Abstract][Full Text] [Related]
15. 6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging.
Kondoh T; Bannai M; Nishino H; Torii K
Exp Neurol; 2005 Mar; 192(1):194-202. PubMed ID: 15698634
[TBL] [Abstract][Full Text] [Related]
16. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
17. Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival.
Reinhart F; Massri NE; Chabrol C; Cretallaz C; Johnstone DM; Torres N; Darlot F; Costecalde T; Stone J; Mitrofanis J; Benabid AL; Moro C
J Neurosurg; 2016 Jun; 124(6):1829-41. PubMed ID: 26613166
[TBL] [Abstract][Full Text] [Related]
18. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
19. High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.
He Z; Jiang Y; Xu H; Jiang H; Jia W; Sun P; Xie J
Behav Brain Res; 2014 Apr; 263():108-14. PubMed ID: 24462728
[TBL] [Abstract][Full Text] [Related]
20. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
Iwata SI; Nomoto M; Fukuda T
Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
